Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy

 
• By John Davis

Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.

Target
Some patients need unlicensed medicines for their condition • Source: Shutterstock.

More from Deals

More from Business